Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer

The advent of rationally targeted therapies such as small-molecule tyrosine kinase inhibitors (TKIs) has considerably transformed the therapeutic management of a subset of patients with non-small-cell lung cancer (NSCLC) harboring defined molecular abnormalities. When such genetic molecular alterati...

Descripción completa

Detalles Bibliográficos
Autores principales: Faugeroux, Vincent, Pailler, Emma, Auger, Nathalie, Taylor, Melissa, Farace, Françoise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220657/
https://www.ncbi.nlm.nih.gov/pubmed/25414829
http://dx.doi.org/10.3389/fonc.2014.00281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220657/
https://www.ncbi.nlm.nih.gov/pubmed/25414829
http://dx.doi.org/10.3389/fonc.2014.00281

Ejemplares similares